Hepatitis E: The New Challenges of a Peculiar Viral Hepatitis
HEV accounts for over three million clinical cases, 70,000 deaths, and 3,000 stillbirths, and 3.3% of all deaths from viral hepatitis worldwide.
HEV infection mostly affects persons living in resource-limited settings with poor access to clean water and sanitation and can be particularly severe in pregnant women and neonates. In particular, HEV is a significant contributor to global maternal mortality, with reported case-fatality rates of 20–30%. In high-income countries, HEV represents a growing concern particularly in immunocompromised individuals and in patients with chronic liver disease, that are at high risk for the severe disease after HEV infection.
Several diseases, including Guillain-Barré syndrome, neuralgic amyotrophy, glomerulonephritis, cryoglobulinemia, pancreatitis, lymphoma, thrombopenia, meningitis, thyroiditis and myocarditis have been observed in the setting of HEV infection presumably as a consequence of the direct cytopathic tissue damage by HEV replication, along with an overwhelming host immune response. There is limited availability and usage of diagnostic tools for the serologic and/or molecular diagnosis of hepatitis E infection, as well as a paucity of treatment options for severe disease, making effective outbreak response challenging.
Discuss virological and pathological aspects of HEV infection
Describe epidemiological aspects of HEV infection
How to diagnose and to follow-up patients for HEV infection
Describe current and upcoming HEV treatment and prevention strategies
Webinars will be available for unlimited on-demand viewing after live event.